CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes

Gene

Volumn 636, Issue , 2017, Pages 36-41

  Shi, Long ^a   Meng, Tongyu ^c   Zhao, Zhilong ^d   Han, Jinsheng ^e   Zhang, Wei ^f   Gao, Fei ^b   Cai, Jianhui ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

^c The First Hospital of SJZ   (China)

^d JINZHOU MEDICAL UNIVERSITY   (China)

^e Cangzhou Hospital of Traditional Chinese Medicine and Western Medicine Integrated Hebei   (China)

^f HANDAN CENTRAL HOSPITAL   (China)

Author keywords

Cancer immunotherapy; CRISPR; CTLA 4; cytotoxic T lymphocytes; T cell mediated antitumor immunity

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CLASSIFICATION; CRISPR CAS SYSTEM; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; GENETICS; HCT 116 CELL LINE; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; NEOPLASMS; PATHOLOGY; SCID MOUSE;

ANIMALS; APOPTOSIS; CASPASES; CELLS, CULTURED; CRISPR-CAS SYSTEMS; CTLA-4 ANTIGEN; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; DENDRITIC CELLS; HCT116 CELLS; HUMANS; IMMUNOPHENOTYPING; MICE, SCID; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85031753105     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2017.09.010     Document Type: Article

References (44)

1. Bretscher, P., The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 13:2 (1992), 74–76.
2. Bretscher, P., Cohn, M., A theory of self-nonself discrimination. Science 169:3950 (1970), 1042–1049.
3. Brunet, J.F. et al., A new member of the immunoglobulin superfamily—CTLA-4. Nature 328:6127 (1987), 267–270.
4. Collins, A.V. et al., The interaction properties of costimulatory molecules revisited. Immunity 17:2 (2002), 201–210.
5. Damle, N.K. et al., Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes. J. Immunol. 140:6 (1988), 1753–1761.
6. Demaria, S. et al., Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11:2 Pt 1 (2005), 728–734.
7. Dewan, M.Z. et al., Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15:17 (2009), 5379–5388.
8. Dunn, G.P. et al., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:11 (2002), 991–998.
9. Espenschied, J. et al., CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J. Immunol. 170:6 (2003), 3401–3407.
10. Fevery, S. et al., CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia 21:7 (2007), 1451–1459.
11. Freeman, G.J. et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:7 (2000), 1027–1034.
12. Gayet, J. et al., Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:36 (2001), 5025–5032.
13. Grosso, J.F., Jure-Kunkel, M.N., CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun., 13, 2013, 5.
14. Hara, T., Fu, S.M., Hansen, J.A., Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 Antigen). J. Exp. Med. 161:6 (1985), 1513–1524.
15. Ishida, Y. et al., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:11 (1992), 3887–3895.
16. Jenkins, M.K. et al., CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 147:8 (1991), 2461–2466.
17. June, C.H. et al., Role of the CD28 receptor in T-cell activation. Immunol. Today 11:6 (1990), 211–216.
18. Kalergis, A.M. et al., Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2:3 (2001), 229–234.
19. Kim, R., Emi, M., Tanabe, K., Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1 (2007), 1–14.
20. Korman, A.J., Peggs, K.S., Allison, J.P., Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90 (2006), 297–339.
21. Krummel, M.F., Allison, J.P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:2 (1995), 459–465.
22. Kwon, E.D. et al., Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 96:26 (1999), 15074–15079.
23. Lafferty, K.J., Cunningham, A.J., A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53:1 (1975), 27–42.
24. Ledbetter, J.A. et al., CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75:7 (1990), 1531–1539.
25. Lenschow, D.J., Walunas, T.L., Bluestone, J.A., CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14 (1996), 233–258.
26. Lindstein, T. et al., Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:4902 (1989), 339–343.
27. Linsley, P.S., Ledbetter, J.A., The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11 (1993), 191–212.
28. Lute, K.D. et al., Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106:9 (2005), 3127–3133.
29. Mangsbo, S.M. et al., Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 33:3 (2010), 225–235.
30. Martin, P.J. et al., A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J. Immunol. 136:9 (1986), 3282–3287.
31. Mocellin, S., Nitti, D., CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim. Biophys. Acta 1836:2 (2013), 187–196.
32. Pilones, K.A. et al., Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin. Cancer Res. 15:2 (2009), 597–606.
33. Ribas, A., Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 13:Suppl. 4 (2008), 10–15.
34. Saha, A., Chatterjee, S.K., Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand. J. Immunol. 71:2 (2010), 70–82.
35. Salama, A.K., Hodi, F.S., Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 17:14 (2011), 4622–4628.
36. Sanjana, N.E., Shalem, O., Zhang, F., Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11:8 (2014), 783–784.
37. Schmidt-Wolf, I.G. et al., Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 174:1 (1991), 139–149.
38. Schwartz, R.H., A cell culture model for T lymphocyte clonal anergy. Science 248:4961 (1990), 1349–1356.
39. Van Lier, R.A. et al., T cell receptor/CD3 and CD28 use distinct intracellular signaling pathways. Eur. J. Immunol. 21:7 (1991), 1775–1778.
40. Waitz, R. et al., Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72:2 (2012), 430–439.
41. Walunas, T.L. et al., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:5 (1994), 405–413.
42. Weber, J., Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13:Suppl. 4 (2008), 16–25.
43. Yang, Y.F. et al., Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57:18 (1997), 4036–4041.
44. Yin, L.M. et al., Simultaneous application of BrdU and WST-1 measurements for detection of the proliferation and viability of airway smooth muscle cells. Biol. Res., 47, 2014, 75.